Efficacy of early stereotactic body radiotherapy to the primary lung lesion in patients with NSCLC harboring sensitive EGFR mutations treated with first-line EGFR-TKIs

被引：0
|
作者：
Tao, D. [1 ]
Lei, H. [2 ]
Tan, J. [1 ]
Yang, D. [1 ]
Jiang, Y. [1 ]
Zhou, W. [1 ]
Wang, Y. [1 ]
Wu, Y. [1 ]
机构：
[1] Chongqing Univ, Dept Radiat Oncol, Canc Hosp, Chongqing, Peoples R China
[2] Chongqing Univ, Chongqing Canc Multi Omics Big Data Applicat Engn, Canc Hosp, Chongqing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2384
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1351P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Efficacy of EGFR-TKIs Compared with Chemotherapy as First-Line Therapy in Patients with EGFR Rare Mutation Advanced Lung Adenocarcinoma
    Wang, H.
    Li, H.
    Zhang, M.
    Zhang, G.
    Zhang, X.
    Ma, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S985 - S985
  • [22] Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations
    Passaro, Antonio
    Prelaj, Arsela
    Bonanno, Laura
    Tiseo, Marcello
    Tuzi, Alessandro
    Proto, Claudia
    Chiari, Rita
    Rocco, Danilo
    Genova, Carlo
    Sini, Claudio
    Cortinovis, Diego
    Pilotto, Sara
    Landi, Lorenza
    Bennati, Chiara
    Camerini, Andrea
    Toschi, Luca
    Putzu, Carlo
    Cerea, Giulio
    Spitaleri, Gianluca
    Cappuzzo, Federico
    de Marinis, Filippo
    CLINICAL LUNG CANCER, 2019, 20 (02) : E186 - E194
  • [23] An Exploration Study of Mechanisms Underlying Primary Resistance to EGFR-TKIs in Patients Harboring TKI-Sensitive EGFR Mutations
    Ke, Ee
    Chen, Zhihong
    Su, Jian
    Zhang, Xu-Chao
    Guo, Longhua
    Niu, Feiyu
    Zhang, Qiuyi
    Xu, Chongrui
    Wu, Yi Long
    Zhou, Qing
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1195 - S1196
  • [24] Antacid and de novo brain metastases in EGFR-mutant NSCLC patients treated with first-line, first-generation EGFR-TKIs
    Chen, Y-M.
    Lin, M-C.
    Lai, C-H.
    Fang, W-F.
    Chang, H-C.
    Wang, C-C.
    Tseng, C-C.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S132 - S132
  • [25] The Predictive Value of Longitudinal Monitoring of Mutated EGFR in Plasma of Advanced NSCLC Patients on First-Line EGFR-TKIs
    Szpechcinski, A.
    Bryl, M.
    Wojda, E.
    Czyzewicz, G.
    Swiniuch, D.
    Szwiec, M.
    Ramlau, R.
    Sliwinski, P.
    Barinow-Wojewodzki, A.
    Chorostowska-Wynimko, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S434 - S435
  • [26] Efficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFR-TKI in Elderly Patients with NSCLC Harboring Sensitive EGFR Mutations
    Yamada, Y.
    Imai, H.
    Sugiyama, T.
    Minemura, H.
    Kaira, K.
    Kanazawa, K.
    Kasai, T.
    Kaburagi, T.
    Minato, K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S908 - S908
  • [27] Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated with First-Line EGFR-TKIs
    Su, C.
    Jiang, T.
    Zhao, J.
    Li, X.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S409 - S410
  • [28] A Retrospective Single-Center Analysis of Patients with Atypical EGFRm NSCLC Treated with First-Line EGFR-TKIs
    Hong, L.
    Du, R.
    Lee, J. Jack
    Heymach, J. V.
    Le, X.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E28 - E29
  • [29] First-Line EGFR-TKIs Treatment in Stage I Non-Small-Cell Lung Cancer Patients Harboring EGFR Gene Mutations with Postoperative Intrapulmonary Recurrence
    Zhu, Zhouyu
    Chai, Ying
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 1667 - 1672
  • [30] Efficacy of EGFR-TKIs vs TKIs Plus Chemotherapy as First-Line Treatment in EGFR-Mutation Lung Adenocarcinoma With Liver Metastases
    Wang, H.
    Li, M.
    Xing, R.
    Wei, C.
    Ma, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1110 - S1110
12345